Literature DB >> 9826520

Cerebral vasoconstriction during sustained ventricular tachycardia induces an ischemic stress response of brain tissue in rats.

A Hagendorff1, C Dettmers, P Danos, M Hümmelgen, C Vahlhaus, C Martin, G Heusch, B Lüderitz.   

Abstract

Arterial hypotension can cause cerebral ischemia when the autoregulation of the cerebral circulation is exhausted. We hypothesized that sudden cerebral vasoconstriction induced by moderate hypotensive, but hemodynamically stable, sustained ventricular tachycardias (MHT-VT) further compromises cerebral blood flow (CBF) and induces an ischemic stress response of the brain. CBF-measurements and morphological studies were performed without and with blockade of alpha-adrenergic receptors in order to determine the impact of MHT-VF on brain perfusion and brain tissue. Using a model of MHT-VT, CBF was measured with colored microspheres in 71 rats during control conditions. after the onset of MHT-VT, after the onset of moderate hypotensive hypovolemia (MHH), and after additional non- selective (alpha-blockade with phentolamine and selective alpha1-blockade with prazosin, respectively (0.2-0.4 mg/kg body weight). Plasma catecholamine concentrations were measured in 18 additional rats during control conditions. during MHT-VT and during MHH. The occurrence of heat shock protein (hsp) 72 and activated microglia in the brain was analysed in 18 additional rats in controls, after MHT-VT and MHH. After 20 min of the respective induced hypotension, control conditions were restored for a period of 8 h, by stopping VT or by infusion of isotonic saline solution. CBF was 0.98+/-0.16 (mean+/-S.D.) ml/g/min during control conditions at an arterial pressure of 118+/-13 mmHg, 0.50+/-0.05 ml/g/min (P<0.05 v control) during MHT-VT (76+/-4 mm Hg) and 0.75+/-0.14 ml/g/min (P<0.05 v control and v MHT-VT ) during MHH (71 +/- 8 mm Hg). CBF was better preserved with non-selective alpha-blockade during MHT-VT (0.78+/-0.15 ml/g/min, P<0.05 v MHT-VT and control) as well as with selective alpha1-blockade (0.67+/-0.08 ml/g/min, P<0.05 v MHT-VT and control). Plasma catecholamines were elevated during MHT-VT (P<0.05 v control) but not during MHH (P = N.S. v control). hsp 72 and activated microglia were found in hippocampal regions only after MHT-VT (P<0.05 v control and MHH). These morphological changes were prevented by non-selective alpha-blockade. Stable sustained MHT-VT further reduce the already compromised CBF leading to morphological alterations in the brain which are characteristic of an early ischemic stress response. alpha-Blockade prevents alpha1-adrenergic vasoconstriction and attenuates cerebral hypoperfusion.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9826520     DOI: 10.1006/jmcc.1998.0772

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  3 in total

1.  Case report: regional cerebral hypoperfusion induced by ventricular tachycardia - short-term hippocampal hypoperfusion and its potential relationship to selective neuronal damage.

Authors:  A Hagendorff; E Klemm; M Bangard; C Dettmers; C Wolpert; B Schumacher; H J Biersack; F Grünwald; B Lüderitz; D Pfeiffer
Journal:  J Interv Card Electrophysiol       Date:  2001-12       Impact factor: 1.900

2.  Cerebral ischemia increases bone marrow CD4+CD25+FoxP3+ regulatory T cells in mice via signals from sympathetic nervous system.

Authors:  Jianping Wang; Lie Yu; Chao Jiang; Xiaojie Fu; Xi Liu; Menghan Wang; Chunying Ou; Xiaobing Cui; Chengguang Zhou; Jian Wang
Journal:  Brain Behav Immun       Date:  2014-08-07       Impact factor: 7.217

3.  Young Sprague Dawley rats infected by Plasmodium berghei: A relevant experimental model to study cerebral malaria.

Authors:  Sokhna Keita Alassane; Marie-Laure Nicolau-Travers; Sandie Menard; Olivier Andreoletti; Jean-Pierre Cambus; Noémie Gaudre; Myriam Wlodarczyk; Nicolas Blanchard; Antoine Berry; Sarah Abbes; David Colongo; Babacar Faye; Jean-Michel Augereau; Caroline Lacroux; Xavier Iriart; Françoise Benoit-Vical
Journal:  PLoS One       Date:  2017-07-24       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.